Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1972 Jun 24;2(5816):743–744. doi: 10.1136/bmj.2.5816.743

Suppression of Puerperal Lactation with an Ergot Alkaloid: A Double-blind Study

L Varga, P M Lutterbeck, J S Pryor, R Wenner, H Erb
PMCID: PMC1788467  PMID: 4556543

Abstract

A double-blind trial was performed in 60 women to establish the effectiveness of an ergot alkaloid, 2-Br-alpha-ergocryptine (ergocryptine; CB 154), in suppressing puerperal lactation and to compare it with stilboestrol and a placebo. At the doses selected ergocryptine and stilboestrol were equally effective.

Full text

PDF
743

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Billeter E., Flückinger E. Evidence for a luteolytic function of prolactin in the intact cyclic rat using 2-Br-alpha-Ergokryptine (CB 154). Experientia. 1971 Apr 15;27(4):464–465. doi: 10.1007/BF02137315. [DOI] [PubMed] [Google Scholar]
  2. Cassell E. E., Meites J., Welsch C. W. Effects of ergocornine and ergocryptine on growth of 7,12-dimethylbenzanthracene-induced mammary tumors in rats. Cancer Res. 1971 Jul;31(7):1051–1053. [PubMed] [Google Scholar]
  3. Daniel D. G., Bloom A. L., Giddings J. C., Campbell H., Turnbull A. C. Increased factor IX levels in puerperium during administration of diethylstilboestrol. Br Med J. 1968 Mar 30;1(5595):801–803. doi: 10.1136/bmj.1.5595.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Daniel D. G., Campbell H., Turnbull A. C. Puerperal thromboembolism and suppression of lactation. Lancet. 1967 Aug 5;2(7510):287–289. doi: 10.1016/s0140-6736(67)90117-1. [DOI] [PubMed] [Google Scholar]
  5. Daniel D. G., Turnbull A. C., Campbell H., Bloom A. L., Giddings J. C. Puerperal thromboembolism. Br Med J. 1968 Nov 16;4(5628):451–451. doi: 10.1136/bmj.4.5628.451-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Drill V. A., Calhoun D. W. Oral contraceptives and thromboembolic disease. II. Estrogen content of oral contraceptives. JAMA. 1972 Jan 31;219(5):593–596. [PubMed] [Google Scholar]
  7. Drill V. A. Oral contraceptives and thromboembolic disease. I. Prospective and retrospective studies. JAMA. 1972 Jan 31;219(5):583–592. [PubMed] [Google Scholar]
  8. Flückiger E., Wagner H. R. 2-Br-alpha-Ergokryptin: Beeinflussung von Fertilität und Laktation bei der Ratte. Experientia. 1968 Nov 15;24(11):1130–1131. doi: 10.1007/BF02147804. [DOI] [PubMed] [Google Scholar]
  9. Forsyth I. A., Besser G. M., Edwards C. R., Francis L., Myres R. P. Plasma prolactin activity in inappropriate lactation. Br Med J. 1971 Jul 24;3(5768):225–227. doi: 10.1136/bmj.3.5768.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Frantz A. G., Kleinberg D. L. Prolactin: evidence that it is separate from growth hormone in human blood. Science. 1970 Nov 13;170(3959):745–747. doi: 10.1126/science.170.3959.745. [DOI] [PubMed] [Google Scholar]
  11. Friesen H., Guyda H., Hardy J. The biosynthesis of human growth hormone and prolactin. J Clin Endocrinol Metab. 1970 Dec;31(6):611–624. doi: 10.1210/jcem-31-6-611. [DOI] [PubMed] [Google Scholar]
  12. Gillibrand P. N., Huntingford P. J. Inhibition of lactation with combined oestrogen and progestogen. Br Med J. 1968 Dec 21;4(5633):769–769. doi: 10.1136/bmj.4.5633.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gunther M., Kohorn E. I. Oestrogens and puerperal thrombosis. Br Med J. 1968 Dec 21;4(5633):769–769. doi: 10.1136/bmj.4.5633.769-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Heuson J. C., Waelbroeck-van Gaver C., Legros N. Growth inhibition of rat mammary carcinoma and endocrine changes produced by 2-Br-alpha-ergocryptine, a suppressor of lactation and nidation. Eur J Cancer. 1970 Oct;6(5):353–356. doi: 10.1016/0014-2964(70)90031-9. [DOI] [PubMed] [Google Scholar]
  15. Hökfelt T., Fuxe K. Effects of prolactin and ergot alkaloids on the tubero-infundibular dopamine (DA) neurons. Neuroendocrinology. 1972;9(2):100–122. doi: 10.1159/000122042. [DOI] [PubMed] [Google Scholar]
  16. Jeffcoate T. N., Miller J., Roos R. F., Tindall V. R. Puerperal thromboembolism in relation to the inhibition of lactation by oestrogen therapy. Br Med J. 1968 Oct 5;4(5622):19–25. doi: 10.1136/bmj.4.5622.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Llewellyn-Jones D. Inhibition of lactation by oestrogens. Br Med J. 1968 Nov 9;4(5627):387–387. doi: 10.1136/bmj.4.5627.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lutterbeck P. M., Pryor J. S., Varga L., Wenner R. Treatment of non-puerperal galactorrhoea with an ergot alkaloid. Br Med J. 1971 Jul 24;3(5768):228–229. doi: 10.1136/bmj.3.5768.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pasteels J. L., Danguy A., Frérotte M., Ectors F. Inhibition de la sécrétion de prolactine par l'ergocornine et la 2-Br-alpha-ergocryptine: action directe sur l'hypophyse en culture. Ann Endocrinol (Paris) 1971 Jan-Feb;32(1):188–192. [PubMed] [Google Scholar]
  20. Quadri S. K., Meites J. Regression of spontaneous mammary tumors in rats by ergot drugs. Proc Soc Exp Biol Med. 1971 Dec;138(3):999–1001. doi: 10.3181/00379727-138-36036. [DOI] [PubMed] [Google Scholar]
  21. Yanai R., Nagasawa H. Effects of ergocornine and 2-Br-alpha-ergokryptin (CB-154) on the formation of mammary hyperplastic alveolar nodules and the pituitary prolactin levels in mice. Experientia. 1970 Jun 15;26(6):649–650. doi: 10.1007/BF01898742. [DOI] [PubMed] [Google Scholar]
  22. Yanai R., Nagasawa H. Inhibition by ergocornine and 2-Br-alpha-ergocryptin of spontaneous mammary tumor appearance in mice. Experientia. 1971 Aug;27(8):934–935. doi: 10.1007/BF02135754. [DOI] [PubMed] [Google Scholar]
  23. Yanai R., Nagasawa H. Suppression of mammary hyperplastic nodule formation and pituitary prolactin secretion in mice induced by ergocornine or 2-bromo-a-ergocryptine. J Natl Cancer Inst. 1970 Dec;45(6):1105–1112. [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES